tirzepatide cardiovascular outcomes trial 2024 Comparison of and dulaglutide on major adverse events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics Bridging the gap between GLP1-receptor
Description
Contrasting Tirzepatide with other GLP-1 agonists and considering its combinatory usage with other diabetes medications are two critical areas
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
B.SuterT
These reactions usually fade within a day or two and do not interfere with treatment
These trials collectively represent some of the most rigorous long-term safety assessments ever conducted for a weight management medication
